一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括LY3537982；Pembrolizumab；Placebo；Cisplatin；Carboplatin；Pemetrexed，当前状态为招募中。登记地点显示中国北京、长春、长沙、常州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
LY3537982；Pembrolizumab；Placebo；Cisplatin；Carboplatin；Pemetrexed · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital Chinese Academy of Medical Science · 北京
- Beijing Cancer hospital · 北京
- Jilin Province Tumor Hospital · 长春
- Hunan Cancer Hospital · 长沙
- The First People's Hospital of Changzhou · 常州
- Sichuan Cancer hospital · 成都
- West China Hospital, Sichuan University · 成都
- Fujian Cancer Hospital · 福州
- The First Affiliated Hospital of Guangzhou Medical University · 广州
- Hainan General Hospital · 海口
- The First Affiliated Hospital, Zhejiang University · 杭州
- Sir Run Run Shaw Hospital · 杭州
- Zhejiang Cancer Hospital · 杭州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Jinan Central Hospital · 济南
- Shandong Cancer Hospital · 济南
- Taizhou Hospital of Zhejiang Province · 临海
- LinYi Cancer Hospital · 临沂
- Liuzhou People's Hospital · 柳州
- The First Affiliated Hospital of Nanchang University · 南昌
- Nanjing First Hospital · 南京
- Shanghai Chest Hospital · 上海
- Tianjin Medical University Cancer Institute & Hospital · 天津
- Xinjiang Medical University Cancer Hospital - Urumqi · 乌鲁木齐
- Tongji Hospital Tongji Medical,Science & Technology · 武汉
- Wuhan Union Hospital · 武汉
- Renmin Hospital of Wuhan University · 武汉
- The First Affiliated Hospital of Xi'an Jiaotong University · 西安
- Xiangyang Central Hospital · 襄阳
- Yichang Central People's Hospital · 宜昌
- Affiliated Hospital of Guangdong Medical University · 湛江
- ZhuZhou Central Hospital · Zhuzhou
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.
- * Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label).
- * Must have disease with evidence of KRAS G12C mutation.
- * Must have known programmed death-ligand 1 (PD-L1) expression
- Part A: Greater than or equal to (≥)50 percent (%).
- Part B: 0% to 100%.
- Part C: \<50%.
- * Must have measurable disease per RECIST v1.1.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06119581；登记信息更新于 2026-10-07；本站同步于 2026-10-08，中国中心当前名额未经人工确认。